Research Topics
| David CarboneSummaryAffiliation: Vanderbilt University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The molecular basis of lung cancer: molecular abnormalities and therapeutic implicationsPierre P Massion
Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6838, USA
Respir Res 4:12. 2003....- Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcomeDavid P Carbone
Hamon Center for Therapeutic Concology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA
J Clin Oncol 23:5099-107. 2005..To determine the ability to induce tumor-specific immunity with individual mutant K-ras-or p53-derived peptides and to monitor clinical outcome... - VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabDavid P Carbone
Vanderbilt University Medical Center, 685 PRB, 2220 Pierce Avenue, Nashville, TN 37232, United States
Lung Cancer 69:337-40. 2010..We found that VeriStrat could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen... - Biomarkers of response to gefitinib in non-small-cell lung cancerDavid P Carbone
Vanderbilt-Ingram Cancer Center, Department of Medicine, Nashville, TN 37232-6838, USA
Nat Clin Pract Oncol 1:66-7. 2004 - Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigmsDavid P Carbone
Thoracic Oncology Center, Vanderbilt Ingram Cancer Center, Nashville, TN, USA
Clin Lung Cancer 12:261-71. 2011..It is hoped that such advances and a changing treatment paradigm will ultimately result in greater survival for patients with early NSCLC... - Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503Joseph M Amann
Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA
J Thorac Oncol 5:169-78. 2010.... - Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancerLi Yang
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Cancer Res 67:5587-93. 2007..This effect is reversible in a subset of NSCLC upon treatment with an EGFR TKI... - Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cellsSergey V Novitskiy
Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University, 220 Pierce Avenue, Nashville, TN 37232, USA
J Thorac Oncol 5:1410-5. 2010..The purpose of the study was to elucidate the molecular mechanisms responsible for the development of neutropenia during the combination treatment... - Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibVincent A Miller
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 26:1472-8. 2008..We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response... - Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGFYuhui Huang
Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232 6838, USA
Blood 110:624-31. 2007..Our findings suggest that selective blockade of VEGFR-2 rather than of both receptors may optimally overcome the adverse hematologic consequences of elevated VEGF levels found in malignancy... - Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancersNobuhiro Haruki
Division of Hematology, Allergy/Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Cancer Res 65:3555-61. 2005..These observations support a role for Notch3 signaling in lung cancer, and one potential mechanism of maintaining the neoplastic phenotype is through the modulation of the EGF pathway... - Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi
Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6838, USA
J Natl Cancer Inst 99:838-46. 2007.... - Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancerJoseph Amann
Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
Cancer Res 65:226-35. 2005..Thus, in addition to EGFR mutations, other factors in NSCLC cells, such as high expression of ErbB family members, may constitutively activate AKT and sensitize cells to EGFR inhibitors... - Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptorLi Yang
Department of Medicine, The Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
J Clin Invest 111:727-35. 2003..Our data demonstrate an important role for the EP2 receptor in PGE(2)-induced inhibition of DC differentiation and function and the diminished antitumor cellular immune responses in vivo... - A training-testing approach to the molecular classification of resected non-small cell lung cancerNoboru Yamagata
Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6838, USA
Clin Cancer Res 9:4695-704. 2003.... - Molecular fingerprinting in human lung cancerKiyoshi Yanagisawa
Vanderbilt-Ingram Cancer Center and Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Clin Lung Cancer 5:113-8. 2003..This review aims to summarize the state of the art of gene and protein expression profiling for non-small-cell lung cancer.. - Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancRoy S Herbst
Department of Thoracic/Head and Neck Medical Oncology, Biostatistics and Diagnostic Radiology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 23:2544-55. 2005..6 months, with progression-free survival of 6.2 months. CONCLUSION: Encouraging antitumor activity and safety of A + T support further development of this combination for patients with advanced NSCLC and other solid tumors... - Proteomic patterns of tumour subsets in non-small-cell lung cancerKiyoshi Yanagisawa
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232-6838, USA
Lancet 362:433-9. 2003.... - Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancerPinar B Yildiz
Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA
J Thorac Oncol 2:893-901. 2007..We hypothesized that matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) analysis of the most abundant peptides in the serum may distinguish lung cancer cases from matched controls... - Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxelIldiko Csiki
Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA
Clin Cancer Res 11:6634-40. 2005..However, in light of the apparent survival prolongation in the subset with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE(2) synthesis in NSCLC seems warranted... - Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiationMikhail M Dikov
Vanderbilt University, 2200 Pierce Avenue, 648 PB, Nashville, TN 37232, USA
J Immunol 174:215-22. 2005..The data suggest that therapeutic strategies attempting to reverse the immunosuppressive effects of VEGF in cancer patients might be more effective if they specifically targeted VEGFR1... - Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonismLi Yang
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Cancer Res 66:9665-72. 2006..Selective antagonism of the EP4 receptor may thus represent a novel therapeutic approach for the treatment of cancer and especially its propensity to metastasize... - Genomics and proteomics: emerging technologies in clinical cancer researchChristine H Chung
Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
Crit Rev Oncol Hematol 61:1-25. 2007..We will present a framework for future directions of these technologies and how we believe they should be applied in clinical studies... - Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancersJun Konishi
Division of Hematology and Medical Oncology and Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
Cancer Res 67:8051-7. 2007..In conclusion, these results support the hypothesis that inhibition of Notch activation using a gamma-secretase inhibitor represents a potential new approach for the targeted therapy of lung cancer... - Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancerHeath B Acuff
Vanderbilt Ingram Cancer Center and Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232 6840, USA
Cancer Res 66:7968-75. 2006..The use of the Hu/Mu ProtIn chip allows us to distinguish tumor- and host-derived proteases and guides the further analysis of the significance of these genes in tumor progression... - VEGF inhibits T-cell development and may contribute to tumor-induced immune suppressionJoyce E Ohm
Department of Cancer Biology and Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
Blood 101:4878-86. 2003..These data demonstrate that at pathophysiologic concentrations, VEGF interferes with the development of T cells from early hematopoetic progenitor cells and this may contribute to tumor-associated immune deficiencies... - Improving the evaluation of new cancer treatments: challenges and opportunitiesMace L Rothenberg
Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, Tennessee 37232 6307, USA
Nat Rev Cancer 3:303-9. 2003..How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?.. - Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell linesYasushi Adachi
Vanderbilt-Ingram Cancer Center and Department of Medicine, Vanderbilt University, Nashville, Tennessee 37232, USA
Gastroenterology 123:1191-204. 2002..CONCLUSIONS: Anti-tumor activity of IGF-Ir/tf is mediated through inhibition of Akt-1 and enhances the efficacy of chemotherapy. Adenovirus IGF-Ir/482st may be a useful anticancer therapeutic for colorectal carcinoma... - Profiles in variation: lung carcinogenesisDavid P Carbone
Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University, 685 Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232, USA
Cancer Prev Res (Phila) 2:695-7. 2009.... - Integration of molecular profiling into the lung cancer clinicWilliam Pao
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 15:5317-22. 2009..Implementation will facilitate realization of the promise of molecularly tailored therapy, which could lead to more effective treatments with fewer side effects... - Significance of p63 amplification and overexpression in lung cancer development and prognosisPierre P Massion
Department of Medicine, The Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, 2200 Pierce Avenue, PRB 640, Nashville, Tennessee 37232 6838, USA
Cancer Res 63:7113-21. 2003..These observations suggest that p63 genomic amplification has an early role in lung tumorigenesis and deserves additional evaluation as a biomarker for lung cancer progression... - Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic miceThao P Dang
Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
Oncogene 22:1988-97. 2003.... - Role of p63 amplification and overexpression in lung cancer developmentPierre P Massion
Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Nashville, TN 37232-6838, USA
Chest 125:102S. 2004 - Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasisLi Yang
Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Cancer Cell 13:23-35. 2008..Together, these data indicate that Gr-1+CD11b+ cells contribute to TGFbeta-mediated metastasis through enhancing tumor cell invasion and metastasis... - Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patientsChristine H Chung
Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
Cancer Epidemiol Biomarkers Prev 19:358-65. 2010.... - Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancerLuping Lin
Department of Cancer Biology, Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Cancer Res 70:632-8. 2010..These findings rationalize a mechanistic approach to lung cancer treatment based on Notch3 receptor-targeted therapeutic development... - Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapyLuigi Moretti
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Oncologist 14:1106-15. 2009..Here, we investigated the association between different clinicopathological features and postoperative therapy and local control and survival in patients with resected pN2 NSCLC... - Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancerJeffrey M Albert
Department of Radiation Oncology, Vanderbilt University, 1301 Medical Center Drive, B 902 The Vanderbilt Clinic, Nashville, TN 37232 5671, USA
Cancer Epidemiol Biomarkers Prev 16:1845-51. 2007..Previous studies have examined the prognostic value of clusterin expression in various malignancies. In the present study, we examined clusterin staining in tumors resected from patients with non-small cell lung cancer (NSCLC)... - Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometryJoseph M Amann
Department of Cancer Biology, Veterans Affairs Medical Center, Vanderbilt University, Nashville, TN 37232-6307, USA
Clin Cancer Res 12:5142-50. 2006.... - Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancerIldiko Csiki
Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232-6838, USA
Cancer Res 66:143-50. 2006..We also show that thioredoxin-1 stabilizes HIF-1alpha to induce hypoxia-responsive genes under normoxic conditions. Our results identify two new mechanisms for regulation of COX-2 expression in NSCLC... - Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesisLi Yang
Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Cancer Cell 6:409-21. 2004..Our data provide evidence that Gr+CD11b+ cells of immune origin induced by tumors directly contribute to tumor growth and vascularization by producing MMP9 and differentiating into ECs... - Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinomaEric T Shinohara
Department of Radiation Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Cancer 103:1685-92. 2005..95; P = 0.0046) and death (hazard ratio, 2.74; P = 0.0086). CONCLUSIONS: The nuclear presence of survivin may be an independent biomarker for disease recurrence and overall survival in patients with resected Stage I and II NSCLC... - Tumor-host immune interactions and dendritic cell dysfunctionLi Yang
Vanderbilt University School of Medicine, Department of Cancer Biology, The Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, USA
Adv Cancer Res 92:13-27. 2004..Finally, we will discuss altered dendritic cell function and differentiation in some detail, as it is likely to be one of the most fundamental mechanisms by which tumors escape immune responses... - Immune dysfunction in cancer patientsJoyce E Ohm
Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Oncology (Williston Park) 16:11-8. 2002..This review will encompass the major mechanisms responsible for tumor evasion of immune surveillance and highlight a role for VEGF as a principal contributor to tumor-associated immune deficiencies... - Proteomic patterns of preinvasive bronchial lesionsS M Jamshedur Rahman
Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt-Ingram Comprehensive Cancer Center, 2220 Pierce Avenue, Nashville, TN 37232-6838, USA
Am J Respir Crit Care Med 172:1556-62. 2005..Although further study is needed to validate this approach and to identify biomarkers of tumor development, this is a first step toward a new proteomic characterization of the human model of lung cancer tumorigenesis... - PDGFR-beta expression in small cell lung cancer patientsEric T Shinohara
Department of Medicine, Abington Memorial Hospital, Abington, PA, USA
Int J Radiat Oncol Biol Phys 67:431-7. 2007..Data in non-small-cell cancer cell lines have suggested that PDGFR is a therapeutic target for drug development. In the current study PDGFR-beta expression and prognostic value in small cell lung cancer (SCLC) was investigated... - Proteomics analysis in lung cancer: challenges and opportunitiesTakefumi Kikuchi
Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232, USA
Respirology 12:22-8. 2007..This review summarizes the range of proteomics technologies employed for cancer profiling, and how they have been used to derive new classification models for human lung cancer... - Adenosine receptors in regulation of dendritic cell differentiation and functionSergey V Novitskiy
Division of Hematology Oncology, Vanderbilt University, Nashville, TN 37232, USA
Blood 112:1822-31. 2008..Adenosine signaling through A(2B) receptor is an important factor of aberrant DC differentiation and generation of tolerogenic, angiogenic, and proinflammatory cells... - A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancerRobert Mutter
Vanderbilt University Medical Center, Nashville, Tennessee and University of Texas Southwestern Medical Center, Dallas, Texas, USA
Clin Cancer Res 15:2158-65. 2009..Cyclooxygenase (COX)-2 up-regulation plays an important role in the pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity and radiosensitivity of tumor cells in preclinical trials... - Host A(2B) adenosine receptors promote carcinoma growthSergey Ryzhov
Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN 37232, USA
Neoplasia 10:987-95. 2008..Thus, our data suggest that tumor cells promote their growth by exploiting A(2B) adenosine receptor-dependent regulation of VEGF in host immune cells... - Combination therapy with conditionally replicating adenovirus and replication defective adenovirusChoon-Taek Lee
Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37322-6838, USA
Cancer Res 64:6660-5. 2004..The combination of CRAD and E1-deleted ad induced tumor-specific replication of CRAD and E1-deleted ad and increased the transduction rate and therapeutic efficacy of these viruses in model tumors... - Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597Vicki Keedy
Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA
J Clin Oncol 26:4166-71. 2008..This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to patients with bronchioloalveolar lung carcinoma (BAC)... - Lung cancer: early events, early interventions: conference summary for the 46th Annual Thomas L Petty Aspen Lung ConferenceDavid P Carbone
Experimental Therapeutics Program, Vanderbilt-Ingram Comprehensive Cancer Center, Nashville, TN 37232-6838, USA
Chest 125:167S-72S. 2004 - A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancerRoy S Herbst
Department of Thoracic/Head and Neck Medical Oncology and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 9:4108-15. 2003.... - Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancerYongfen Min
First Department of Internal Medicine, Sapporo Medical University, S 1 W 16, Chuo Ku, Sapporo 060 8543, Japan
Cancer Res 63:6432-41. 2003..The antitumor activity of IGF-Ir/dn is mediated through inhibition of Akt-1 and enhances the efficacy of chemotherapy. Adenovirus-IGF-Ir/482st may be a useful anticancer therapeutic for pancreatic cancer... - Lung cancer vaccines and gene therapyKristen M Hege
Cell Genesys, Inc, 500 Forbes Blvd, South San Francisco, CA 94080, USA
Lung Cancer 41:S103-13. 2003..Earlier stage gene therapy programs targeting the immune system or tumor vasculature hold promise as systemic therapies for treatment of advanced, disseminated disease... - From clinical and pathologic to molecular staging of lung cancerPierre P Massion
Am J Respir Crit Care Med 167:1587-8. 2003 - Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancerChoon-Taek Lee
Department of Internal Medicine, Seoul National University College of Medicine, South Korea
Cancer Gene Ther 10:57-63. 2003..These findings suggest that these ad-IGF-IR/dn (950, 482) have the potential to be effective and practical cancer gene therapy strategies... - H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factorsDmitry I Gabrilovich
H Lee Moffitt Cancer Center, University of South Florida, Tampa 33612, USA
J Leukoc Biol 72:285-96. 2002..Thus, H1(0) histone may be an important factor in normal DC differentiation. Tumor-derived factors may inhibit DC differentiation by affecting H1(0) expression... - Molecular staging and pharmacogenomics. Clinical implications: from lab to patients and backWilbur A Franklin
University of Colorado Health Sciences Center, Denver, CO 80217, USA
Lung Cancer 41:S147-54. 2003..In this review, we will discuss the application of these high-throughput technologies for the study of human lung cancer... - Epidermal growth factor receptor overexpression: the importance of contextDavid P Carbone
J Clin Oncol 21:4268-9. 2003 - Genetic and immunologic therapies for lung cancerStephen G Swisher
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Semin Oncol 29:95-101. 2002..g., interferon), or by specific (e.g., anti-idiotype therapy) strategies. These novel strategies are currently in clinical trials and will potentially allow additional therapeutic options for patients resistant to conventional therapies... - Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathwayYoon Jin Lee
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul 110 744, Republic of Korea
Lung Cancer 55:279-86. 2007..We believe that this system can be usefully applied to other cancer targets... - Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinomaArisa Imsumran
First Department of Internal Medicine, Sapporo Medical University, South 1, West 16, Chuo Ku, Sapporo 060 8543, Japan
Carcinogenesis 28:947-56. 2007..Therapeutic blockade of IGF-Ir may be a useful anticancer therapeutic for ESCC... - Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomasWenhua Piao
First Department of Internal Medicine, Sapporo Medical University, Chuo Ku, Sapporo 060 8543, Japan
Mol Cancer Ther 7:1483-93. 2008..This compound did not influence hybrid receptor formation. Thus, NVP-AEW541 may have significant therapeutic utility in human GI carcinomas both alone and in combination with chemotherapy... - Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi
Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
J Clin Oncol 24:5025-33. 2006..Additional investigation of bortezomib in NSCLC is warranted in combination with other drugs known to be active, or using different schedules... - Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancerDavid I Rosenthal
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Thorac Oncol 1:38-45. 2006.... - Genetic blockade of the insulin-like growth factor 1 receptor for human malignancyYasushi Adachi
First Department of Internal Medicine, Sapporo Medical University, Sapporo, 060-8543, Japan
Novartis Found Symp 262:177-89; discussion 190-2, 265-8. 2004..These studies confirm the validity of IGF-1R as a therapeutic target and genetic blockade as a potential strategy for several malignancies, including lung, colon and pancreatic carcinoma... - Advances and challenges in aerodigestive epithelial cancer: meeting summary and research opportunitiesJennifer R Grandis
Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Cancer Res 67:7556-8. 2007 - In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27Choon Taek Lee
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
Cancer Res 66:372-7. 2006..Moreover, this replication increased the therapeutic gene transfer rate and enhanced its antitumor effects...
Research Grants
- Molecular Signatures of Lung CancerDavid Carbone; Fiscal Year: 2007..Important markers in proteomic profiles will be identified, and together with genomic and cDNA markers, clinically feasible assays will be developed and their robustness tested in prospective studies. ..
- VEGF MEDIATED SIGNALING IN TUMOR/HOST INTERACTIONSDavid Carbone; Fiscal Year: 2007..abstract_text> ..
- MOLECULAR THERAPEUTICS OF CANCERDavid Carbone; Fiscal Year: 2003..This award would allow me additional time to further patient-oriented research at the, Vanderbilt Cancer Center and time to mentor fellow and junior faculty patient-oriented research projects. ..
- VEGF MEDIATED SIGNALING IN TUMOR/HOST INTERACTIONSDavid Carbone; Fiscal Year: 2002....